PD-1 controls differentiation, survival, and TCR affinity evolution of stem-like CD8+ T cells
Jyh Liang HoriD, Edward C. SchromiD, Abigail Wong-RolleiD, Luke F. VistainiD, Wanjing ShangiD, Qiang Dong, Chen Ning ZhaoiD, Chengcheng JiniD, Ronald N. GermainiD
Abstract
Stem-like progenitors are a critical subset of cytotoxic T cells that self-renew and give rise to expanded populations of effector cells critical for successful checkpoint blockade immunotherapy. Emerging evidence suggests that the tumor-draining lymph nodes can support the continuous generation of these stem-like cells that replenish the tumor sites and act as a critical source of expanded effector populations, underlining the importance of understanding what factors promote and maintain activated T cells in the stem-like state. Using advanced 3D multiplex immunofluorescence imaging, here we identified antigen-presentation niches in tumor-draining lymph nodes that support the expansion, maintenance, and affinity evolution of a unique population of TCF-1+PD-1+SLAMF6hi stem-like CD8+ T cells. Our results show that contrary to the prevailing view that persistent TCR signaling drives terminal effector differentiation, prolonged antigen engagement well beyond the initial priming phase sustained the proliferation and self-renewal of these stem-like T cells in vivo. The inhibitory PD-1 pathway plays a central role in this process by mediating the fine-tuning of TCR and co-stimulatory signal input that enables selective expansion of high affinity TCR stem-like clones, enabling them to act as a renewable source of high affinity effector cells. PD-1 checkpoint blockade disrupts this fine tuning of input signaling, leading to terminal differentiation to the effector state or death of the most avid anti-tumor stem-like cells. Our results thus reveal an unexpected relationship between TCR ligand affinity recognition, a key negative feedback regulatory loop, and T cell stemness programming. Furthermore, these findings raise questions about whether anti-PD-1 checkpoint blockade during cancer immunotherapy provides a short-term anti-tumor effect that comes at the cost of diminishing efficacy due to progressive loss of these critical high affinity stem-like precursors.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 56
- FWCI
- 22.53
- Field percentile
- top 1%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Stem-like PD-1+TCF-1+ CD8+ T cells result from helpless priming and rely on CD4+ T-cell help to complete their cytotoxic effector differentiation
Julia Busselaar, Douwe M. T. Bosma, … Jannie G. Borst·Journal for ImmunoTherapy of CancerPeer-reviewed·Apr 1, 2026
- PD-1-Targeted IL-2v Expands a Novel Stem-like T Cell Subset Distinct from Anti-PD-1 Therapy to Enhance Effector Differentiation
Elzbieta Gralinska, Caterina Scirgolea, … Laura Codarri Deak·bioRxiv·Aug 20, 2026
- Dendritic cell PD-L2 restrains intratumoral CD8+ T cell immunity
Jinwoo Nah, Amanda Sun, … Chrysothemis C. Brown·bioRxiv·Sep 16, 2026
- The degree of T cell stemness differentially impacts the potency of adoptive cancer immunotherapy in a Lef-1 and Tcf-1 dependent manner.
G. O. Rangel Rivera, C. J. Dwyer, … C. M. Paulos·bioRxiv·Mar 8, 2023
- PD-1 prelimits both the cytotoxic and exhaustion potential in thymic CD8+ T cells and impacts the maintenance of peripheral tumor immunity
Zhiming Mao, Jacob B. Hirdler, … Haidong Dong·bioRxiv·Jan 18, 2025
- TGF--dependent Lymphoid Tissue Residency of Stem-like T cells Limits the Response to Tumor Vaccine